[1] 沈文斌,祝淑钗,李任.非小细胞肺癌放疗所致放射性食管损伤的研究进展[J].中华放射肿瘤学杂志,2006,15:207-210. [2] Palma DA,Senan S,Oberije C,et al. Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis[J]. Int J Radiat Oncol Biol Phys,2013,87:690-696. [3] Werner-Wasik M,Yorke E,Deasy J,et al. Radiation dose-volume effects in the esophagus[J]. Int J Radiat Oncol Biol Phys,2010,76(3 Suppl):86-93. [4] Bradley J,Deasy JO,Bentzen S,et al. Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma[J]. Int J Radiat Oncol Biol Phys,2004,58:1106-1113. [5] Huang EX,Bradley JD,El Naqa I,et al. Modeling the risk of radiation-induced acute esophagitis for combined Washington University and RTOG trial 93-11 lung cancer patients[J]. Int J Radiat Oncol Biol Phys,2012,82:1674-1679. [6] Ozgen A,Hayran M,Kahraman F. Mean esophageal radiation dose is predictive of the grade of acute esophagitis in lung cancer patients treated with concurrent radiotherapy and chemotherapy[J]. J Radiat Res,2012,53:916-922. [7] Saunders M,Dische S,Barrett A,et al. Continuous hyperfractionated accelerated radiotherapy(CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial[J].Lancet,1997,350:161-165. [8] Bonner JA,Sloan JA,Shanahan TG,et al. Phase Ⅲ comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma[J]. J Clin Oncol,1999,17:2681-2691. [9] Gazula A,Baldini EH,Chen A,et al. Comparison of once and twice daily radiotherapy for limited stage small-cell lung cancer[J]. Lung,2014,192:151-158. [10] O′Rourke N,Roque IFM,Farre Bernado N,et al. Concurrent chemoradiotherapy in non-small cell lung cancer[DB/CD].Syst Rev,2010(6):CD002140. [11] Vokes EE,Herndon JE 2nd,Crawford J,et al. Randomized phase Ⅱ study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage ⅢB non-small-cell lung cancer: cancer and leukemia group B study 9431[J]. J Clin Oncol,2002,20:4191-4198. [12] Grills IS,Yan D,Martinez AA,et al. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy(IMRT),3D conformal radiation,and elective nodal irradiation[J]. Int J Radiat Oncol Biol Phys,2003,57:875-890. [13] Chang JY,Balter PA,Dong L,et al. Stereotactic body radiation therapy in centrally and superiorly located stage Ⅰ or isolated recurrent non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys,2008,72:967-971. [14] Curran WJ Jr,Paulus R,Langer CJ,et al. Sequential vs. concurrent chemoradiation for stage Ⅲ non-small cell lung cancer: randomized phase Ⅲ trial RTOG 9410[J]. J Natl Cancer Inst,2011,103:1452-1460. [15] De Ruysscher D,Van Meerbeeck J,Vandecasteele K,et al. Radiation-induced oesophagitis in lung cancer patients. Is susceptibility for neutropenia a risk factor[J]? Strahlenther Onkol,2012,188:564-567. [16] Yuan ST,Brown RK,Zhao L,et al. Timing and intensity of changes in FDG uptake with symptomatic esophagitis during radiotherapy or chemo-radiotherapy[J/OL]. Radiat Oncol,2014,9:37[2014-04-01].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996188/. [17] Nijkamp J,Rossi M,Lebesque J,et al. Relating acute esophagitis to radiotherapy dose using FDG-PET in concurrent chemo-radiotherapy for locally advanced non-small cell lung cancer[J].Radiother Oncol,2013,106:118-123. [18] 张莉,王绿化,杨明,等.单核苷酸多态性与肺癌放射性食管炎相关性的研究[J].中华放射肿瘤学杂志,2008,17:175-179. [19] Guerra JL,Gomez D,Wei Q,et al. Association between single nucleotide polymorphisms of the transforming growth factor beta1 gene and the risk of severe radiation esophagitis in patients with lung cancer[J]. Radiother Oncol,2012,105:299-304. [20] Brizel DM,Wasserman TH,Henke M,et al. Phase Ⅲ randomized trial of amifostine as a radioprotector in head and neck cancer[J]. J Clin Oncol,2000,18:3339-3345. [21] Movsas B,Scott C,Langer C,et al. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01[J]. J Clin Oncol,2005,23:2145-2154. [22] Komaki R,Lee JS,Milas L,et al. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small cell lung cancer: report of a randomized comparative trial[J]. Int J Radiat Oncol Biol Phys,2004,58:1369-1377. [23] Antonadou D,Coliarakis N,Synodinou M,et al. Randomized phase Ⅲ trial of radiation treatment+/-amifostine in patients with advanced-stage lung cancer[J]. Int J Radiat Oncol Biol Phys,2001,51:915-922. [24] Kim H,Bernard ME,Epperly MW,et al. Amelioration of radiation esophagitis by orally administered p53/Mdm2/Mdm4 inhibitor(BEB55) or GS-nitroxide[J]. In Vivo,2011,25:841-848.
2014, Vol. 23 
